These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38850589)

  • 1. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Sep; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study.
    Huang SP; Guisinger A; Averell C; Bell CF; Rubin B
    Rheumatol Ther; 2023 Jun; 10(3):551-562. PubMed ID: 36738424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
    Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
    BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Economic Burden of Lupus Nephritis: A Systematic Literature Review.
    Thompson JC; Mahajan A; Scott DA; Gairy K
    Rheumatol Ther; 2022 Feb; 9(1):25-47. PubMed ID: 34731412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
    Bell CF; Huang SP; Cyhaniuk A; Averell CM
    Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis.
    Garal-Pantaler E; Schultze M; Georgiou ME; Pignot M; Gairy K; Hunnicutt JN
    Rheumatol Ther; 2024 Feb; 11(1):113-127. PubMed ID: 38001304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
    Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
    J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
    [No Abstract]   [Full Text] [Related]  

  • 17. Referral and evaluation for kidney transplantation among patients with lupus nephritis-related end-stage kidney disease.
    McPherson L; Plantinga LC; Howards PP; Kramer M; Pastan SO; Patzer RE
    Lupus; 2024 Jan; 33(1):48-57. PubMed ID: 38019182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims.
    Garris C; Shah M; Farrelly E
    Cost Eff Resour Alloc; 2015; 13():9. PubMed ID: 26019689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
    Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
    Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.